Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience (TWST) CEO and director Emily M. Leproust reported a transaction on 10/30/2025: the disposition of 31,379 shares of common stock at $31.4443 per share. The filing states these shares were sold to cover tax withholding tied to the vesting of performance stock units, pursuant to the company’s equity plan “sell to cover” election, and were not discretionary trades.
Following the transaction, Leproust beneficially owns 738,809 common shares directly. Derivative holdings listed include employee stock options, such as 150,879 options at an exercise price of $8.82 and 266,539 options at $26.66, among others with varying vesting and expiration terms.
Twist Bioscience (TWST) reported an insider transaction by its Chief Financial Officer, Adam Laponis. On 10/30/2025, the CFO sold 5,517 shares of common stock at $31.4443 per share. According to the filing, these shares were sold to satisfy tax withholding obligations tied to the vesting of Performance Stock Units and were executed as a mandated “sell to cover,” not a discretionary trade.
Following the transaction, the reporting person beneficially owns 111,008 shares directly.
Twist Bioscience (TWST) insider transaction: the Chief Accounting Officer reported a sale of 1,016 shares of common stock on 10/30/2025 at a price of $31.4443 per share. The filing states the sale was a mandated “sell to cover” to satisfy tax withholding obligations tied to the vesting of Performance Stock Units, and not a discretionary trade. Following the transaction, the reporting person beneficially owned 51,030 shares, held directly.
Twist Bioscience (TWST): insider equity award update. President and COO Patrick John Finn acquired 79,785 shares of common stock at $0 on October 28, 2025, recorded as an “A” (acquisition). Following this transaction, he beneficially owns 286,280 shares directly. The shares reflect Performance Stock Units for which target criteria were determined to have been met on October 28, 2025. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration as provided in the award agreement.
Twist Bioscience (TWST): Form 4 insider update. Company officer Dennis Cho reported acquisition of 29,518 shares of common stock on 10/28/2025 at a price of $0, reflecting Performance Stock Units (PSUs) with target criteria determined to be met. Following this transaction, beneficial ownership stands at 128,228 shares, held directly.
The filing notes that 60% of these PSUs remain subject to time-based vesting and are scheduled to vest on October 1, 2026, contingent on continued service or potential acceleration under the award agreement. Role: Senior Vice President, Chief Legal Officer & Corporate Secretary.
Twist Bioscience (TWST) reported an insider equity award. The company’s SVP of Human Resources acquired 35,513 shares of common stock at $0 on October 28, 2025, tied to Performance Stock Units whose target criteria were met.
Following the transaction, the reporting person beneficially owns 150,191 shares. According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, contingent on continued service or acceleration as provided in the agreement.
Twist Bioscience (TWST) reported an insider equity award for its CEO and director, Emily M. Leproust. On 10/28/2025, she acquired 168,976 shares of common stock at $0, tied to Performance Stock Units whose target criteria were determined to have been met. The filing notes that 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement.
Following the transaction, Leproust beneficially owns 770,188 shares directly. The filing also lists existing employee stock options, including grants with exercise prices of $8.82, $26.66, $23.33, and $67.85, with various vesting and expiration terms as disclosed.
Twist Bioscience (TWST) reported an equity award to its Chief Accounting Officer, Robert F. Werner. A Form 4 shows an acquisition of 5,633 shares at $0 on October 28, 2025, tied to performance stock units where target criteria were met.
According to the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration under the award agreement. Following the transaction, beneficial ownership stands at 52,046 shares, held directly.
Twist Bioscience (TWST) reported an insider equity award. CFO Adam Laponis acquired 25,000 shares of common stock at $0 on October 28, 2025, tied to performance stock units whose target criteria were determined to have been met on that date.
After the transaction, he beneficially owned 116,525 shares, held directly. Per the award terms, 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or potential acceleration under the agreement.
Twist Bioscience (TWST) disclosed a Form 4 for its President and COO, Patrick John Finn. On 10/23/2025, he sold 2,240 shares of common stock at $30.875 per share.
The filing explains the sale was a mandated “sell to cover” to satisfy tax withholding tied to the vesting of Restricted Stock Units, and it does not represent discretionary trading. After this transaction, Finn beneficially owned 206,495 shares, held directly.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
